Publications

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. by Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M and Jones RN. published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S81-S93

Surveillance of antibiotic resistance in European ICUs. by Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R and Wolff M published in J. Hosp. Infect. 2001; 48 (3): 161-176

BMS284756 potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (2000). Abstr P40. by Gordon KA, Pfaller MA, Jones RN, Sader HS, Biedenbach DJ, Beach ML and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 1): S26-S27

Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: Report from the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Fusco J, Biedenbach DJ, Pfaller MA and Jones RN. published in Antimicrob. Agents Chemother. 2001; 45 (12): 3599-3600

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. by Gales AC, Reis AO and Jones RN published in J. Clin. Microbiol. 2001; 39 (1): 183-190

Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: Results from the MYSTIC Programme. by Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 125-127

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). by Gales A, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2001; 45 (5): 1463-1466

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). by Gales AC, Jones RN, Forward KR, Linares J, Sader HS and Verhoef J published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S104-S113

Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. by Gales AC, Jones RN, Turnidge J, Rennie R and Ramphal R published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S146-S155

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. by Fix AM, Pfaller MA, Biedenbach DJ, Beach ML and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (2): 141-145

Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates. by Erwin ME, Fix AM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 129-132

Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. by Diekema DJ, Beach ML, Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2001; 7 (3): 152-157

Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997- 1999. by Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN and Beach M published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S114-S132

Oxazolidinone antibiotics. by Diekema DJ and Jones RN published in Lancet 2001; 358 (9297): 1975-1982

Accuracy of broth microdilution and Etest methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999). by Deshpande LM, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 267-269

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria. by Deshpande LM, Gales AC and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (1): 29-35

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods. by Deshpande L, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (5): 437-440

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 257-260

In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (1): 49-53

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. by Biedenbach DJ, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 245-250

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 40 (4): 173-177

Assessment of BMS284756 MIC and 5-µg disk diffusion quality control studies tested against seven American type culture collection strains. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 225-228

Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. by Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A and Jones RN published in J. Clin. Microbiol. 2000; 38 (10): 3715-3717

Global trends in an antimicrobial resistance surveillance system: Results from the MYSTIC Programme. by Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2000; 6 (Suppl 1): 74

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: Resistance implications in the treatment of serious infections. MYSTIC Study Group (Americas). by Pfaller MA and Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 25-37

Quality control guidelines for disk diffusion and broth microdilution antimicrobial susceptibility tests with seven drugs for veterinary applications. by Odland BA, Erwin ME and Jones RN published in J. Clin. Microbiol. 2000; 38 (1): 453-455

Determination of MIC quality control ranges for ABT-733, a novel ketolide antimicrobial agent. Quality Control Study Group. by Marshall SA, Erwin ME, and Jones RN published in J. Clin. Microbiol. 2000; 38 (6): 2462-2463

Evaluation of quinupristin/dalfopristin (Synercid) and RPR 106972 stability in susceptibility testing media. by Marshall SA, Kugler KC, and Jones RN published in Int. J. Antimicrob. Agents 2000; 15 (4): 291-297

Activity of macrolides, lincosamines, streptogramins and fluoroquinolones against Streptococcus pneumoniae and enterococci isolates from the western hemisphere: Example of international surveillance (SENTRY Antimicrobial Surveillance Program )in the development of new drugs. by Lewis MT and Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 15-21

Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. by Lewis RE, Klepser ME, Ernst EJ, Snabes MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (1): 51-55

Frequency of occurrence and antimicrobial susceptibility patterns for pathogens isolated from Latin American patients with a diagnosis of pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (1998). by Lewis MT, Gales AC, Sader HS, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (1): 63-74

Serious streptococcal infections produced by isolates resistant to streptogramins (quinupristin/dalfopristin): Case reports from the SENTRY Antimicrobial Surveillance Program. by Kugler KC, Denys GA, Wilson ML, and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (4): 269-272

Anti-gonococcal activity of gemifloxacin against fluoroquinolone- resistant strains and a comparison of agar dilution and Etest methods. by Jones RN, Deshpande LM, Erwin ME, Barrett MS and Beach ML published in J. Antimicrob. Chemother. 2000; 45 (Suppl 1): 67-70

In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997- 1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Int. J. Antimicrob. Agents. 2000; 15 (2): 111-118

In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 93-98

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Jones RN, Croco MA, Kugler KC, Pfaller MA and Beach ML published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 115-125

Cefditoren activity against nearly 1,000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. by Jones RN, Biedenbach DJ and Johnson DM published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 143-146

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. by Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 2000; 37 (3): 195-201

Evaluation of gemifloxacin (SB-265805, LB20304a): In vitro activity against over 6,000 Gram-positive pathogens from diverse geographic areas. by Jones RN, Pfaller MA and Erwin ME published in Int. J. Antimicrob. Agents 2000; 15 (3): 227-230

Perspectives on the development of new antimicrobial agents for resistant Gram-positive pathogens. by Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 1-8

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY Antimicrobial Surveillance Program. by Jones RN and Pfaller MA. published in Clin. Infect. Dis. 2000; 31 (Suppl 2): S16-23

Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. by Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 1-8

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). by Jones RN and Pfaller MA published in J. Clin. Microbiol. 2000; 38 (11): 4298-4299

Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! by Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2000; 44 (10): 2922-2923

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. by Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 99-105

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). by Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA and Doern GV published in J. Antimicrob. Chemother. 2000; 45 (3): 295-303

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 1997-98. SENTRY Study Group. by Gales AC, Jones RN, Pfaller MA, Gordon KA and Sader HS published in Int. J. Infect. Dis. 2000; 4 (2): 75-84

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. by Gales AC and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 19-36

Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. by Gales AC, Gordon KA, Wilke WW, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 61-64

Oxazolidinones: A review. by Diekema DI and Jones RN published in Drugs 2000; 59 (1): 7-16